Osteo-Pharma
Osteo-Pharma BV is a Dutch Life Sciences company dedicated to developing novel medications and medical devices to improve the local healing of bone fractures and defects. Utilizing its proprietary OsteoActivator platform, the company develops biodegradable films, microspheres, and coatings for implants that facilitate sustained release of small molecule drugs, enhancing bone formation and inhibiting resorption. The company is in mid to late stage pre-clinical development with various projects and aims to initiate first human clinical trials around 2017/2018. Its mission is to deliver innovative solutions for bone healing and regeneration, including treatments for osteoarthritis and coatings for implants to improve osseo-integration.
Industries
Nr. of Employees
small (1-50)
Osteo-Pharma
Osteo-Pharma BV, Pivot Park, Kloosterstraat 9, 5349 AB Oss, The Netherlands
Patents
Compositions and products for use in the treatment of bone fractures and defects
US-11541063-B2
View Details
Compositions and products for use in the treatment of bone fractures and defects
US-11541063-B2
View DetailsProducts
Drug‑eluting biodegradable collagen barrier membrane for guided bone regeneration
Biodegradable collagen membrane coated with a sustained-release drug layer designed to enhance early bone formation in dental procedures (e.g., alveolar ridge preservation) and applicable to fracture/defect healing.
Injectable biodegradable PLGA microspheres for local bone delivery
Injectable PLGA microspheres formulated to release combination therapeutics locally within bone defects or via intraosseous injection to restore subchondral bone remodeling and relieve pain in osteoarthritis-related lesions.
Drug‑eluting implant coatings to enhance osseointegration
Sustained-release coatings applied to orthopedic implants and screws to increase adjacent bone formation and bone-implant contact, based on preclinical implant studies.
Drug‑eluting biodegradable collagen barrier membrane for guided bone regeneration
Biodegradable collagen membrane coated with a sustained-release drug layer designed to enhance early bone formation in dental procedures (e.g., alveolar ridge preservation) and applicable to fracture/defect healing.
Injectable biodegradable PLGA microspheres for local bone delivery
Injectable PLGA microspheres formulated to release combination therapeutics locally within bone defects or via intraosseous injection to restore subchondral bone remodeling and relieve pain in osteoarthritis-related lesions.
Drug‑eluting implant coatings to enhance osseointegration
Sustained-release coatings applied to orthopedic implants and screws to increase adjacent bone formation and bone-implant contact, based on preclinical implant studies.
Services
Collaborative R&D to develop local bone-healing products through preclinical efficacy/safety testing and into clinical trials; includes protocol development and interactions with ethics committees.
Formation of joint ventures and licensing arrangements to combine formulation platforms with manufacturing technologies and to co-develop products for dental and orthopedic markets.
Collaborative R&D to develop local bone-healing products through preclinical efficacy/safety testing and into clinical trials; includes protocol development and interactions with ethics committees.
Formation of joint ventures and licensing arrangements to combine formulation platforms with manufacturing technologies and to co-develop products for dental and orthopedic markets.
Expertise Areas
- Local sustained drug delivery for bone
- Bone regeneration and orthopedic therapeutics
- Dental guided bone regeneration
- Microsphere formulation and injectable delivery
Key Technologies
- PLGA-based biodegradable carriers
- Sustained-release microsphere encapsulation
- Drug-eluting collagen membrane coatings
- Implant surface coating technology
News & Updates
The first patient has been treated in a clinical trial comparing OsteoActivator-P coated membranes versus uncoated membranes for alveolar ridge preservation in the Netherlands.
A joint venture called Bone-Tech to develop a disease-modifying treatment for osteoarthritis of the knee using OsteoActivator microspheres.
The company has obtained approval to test OsteoActivator-P in patients, a membrane to improve bone formation in dental defects.
The European Patent Office issued a notice of intention to grant a patent covering OsteoActivator formulations for bone treatment.
The first patient has been treated in a clinical trial comparing OsteoActivator-P coated membranes versus uncoated membranes for alveolar ridge preservation in the Netherlands.
A joint venture called Bone-Tech to develop a disease-modifying treatment for osteoarthritis of the knee using OsteoActivator microspheres.
The company has obtained approval to test OsteoActivator-P in patients, a membrane to improve bone formation in dental defects.
The European Patent Office issued a notice of intention to grant a patent covering OsteoActivator formulations for bone treatment.